Clinical Trial Update: Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial compared Ultibro with Spiriva alone to reduce exertional dyspnea in moderate-to-severe COPD patients and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva (tiotropium)
• Ultibro (glycopyrronium/indacaterol)

Snippet

Sponsor: Laval University | Conditions: COPD | Phase 4 | Status: COMPLETED